We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Y-Mabs Therapeutics Inc (YMAB) Com USD0.0001

Sell:$8.06 Buy:$8.09 Change: $0.08 (0.98%)
NASDAQ:0.03%
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$8.06
Buy:$8.09
Change: $0.08 (0.98%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$8.06
Buy:$8.09
Change: $0.08 (0.98%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Y-mAbs Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of radioimmunotherapy and antibody-based therapeutic cancer products. Its technologies include its investigational Self-Assembly DisAssembly (SADA) Pretargeted Radioimmunotherapy Platform and bispecific antibodies generated using the Y-BiClone platform. Its advanced product pipeline includes the anti-GD2 therapy DANYELZA (naxitamab-gqgk), a food and drug administration (FDA)-approved treatment for patients with relapsed or refractory neuroblastoma in the bone or bone marrow after a partial response, minor response or stable disease to prior therapy. DANYELZA is a humanized immunoglobulin G, subtype 1k (IgG1k), monoclonal antibody (mAb), that targets ganglioside GD2, which is expressed in various neuroectoderm derived tumors and sarcomas. Omburtamab targets B7-H3, an immune checkpoint molecule that is expressed in tumor cells of several cancer types.

Contact details

Address:
230 PARK AVENUE, SUITE 3350
NEW YORK
10169
United States
Telephone:
+1 (212) 8479841
Website:
https://www.ymabs.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
YMAB
ISIN:
US9842411095
Market cap:
$365.03 million
Shares in issue:
44.79 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Michael Rossi
    President, Chief Executive Officer, Director
  • Thomas Gad
    Vice Chairman of the Board, Chief Business Officer
  • Peter Pfreundschuh
    Chief Financial Officer, Treasurer
  • Joris Wilms
    Chief Operating Officer, Senior Vice President
  • Torben Lund-Hansen
    Senior Vice President, Chief Technical Officer
  • Vignesh Rajah
    Senior Vice President, Chief Medical Officer
  • Susan Smith
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.